Kenvue Inc. $KVUE Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its position in Kenvue Inc. (NYSE:KVUE) by 3.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,606,796 shares of the company’s stock after selling 49,667 shares during the period. The Manufacturers Life Insurance Company owned about 0.08% of Kenvue worth $27,701,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Elyxium Wealth LLC acquired a new stake in Kenvue in the fourth quarter valued at $26,000. Physician Wealth Advisors Inc. increased its position in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares in the last quarter. MV Capital Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth $28,000. Reflection Asset Management acquired a new position in shares of Kenvue during the 4th quarter worth $32,000. Finally, SBI Securities Co. Ltd. boosted its position in shares of Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after buying an additional 1,027 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE KVUE opened at $19.25 on Friday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $22.28. The business has a fifty day moving average of $18.59 and a 200-day moving average of $18.01. The stock has a market cap of $36.95 billion, a price-to-earnings ratio of 22.64, a price-to-earnings-growth ratio of 1.47 and a beta of 0.47.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.24 earnings per share. As a group, analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be issued a $0.21 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. Kenvue’s payout ratio is currently 97.65%.

Analyst Ratings Changes

KVUE has been the topic of a number of research reports. Citigroup lowered their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Barclays lifted their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, UBS Group raised their price objective on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, July 16th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $19.58.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.59% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.